Recent clinical studies (DAPA-HF, EMPEROR-Reduced and EMPEROR-Preserved, SOLOIST-WHF trial) and meta-analysis have demonstrated that sodium–glucose cotransporter-2 inhibitors (SGLT2i) are among the first antidiabetic drugs capable of reducing cardiovascular risks related to HF and improving the prognosis of patients with and without diabetes (Diabetes Therapy)
Diabetes News
Tag: SGLT2 inhibitors
Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
In this article, we briefly review the different mechanisms of action that may explain the renal beneficial effects of SGLT2i and disclose the results of the key renal outcome trials and the subsequent update of related clinical guidelines (Diabetes Therapy)
SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
This supplement summarizes all the evidence of this therapeutic change and reviews the role of these drugs from prevention to management of patients who have already developed complications, such as patients with HF and chronic kidney disease (Diabetes Therapy)
Gliflozins in the Management of Cardiovascular Disease
SGLT2 inhibitors are responsible for major paradigm shifts in the care of patients with or at high risk for heart failure, progression of chronic kidney disease, or both. SGLT2 inhibition improves cardiovascular outcomes in patients with heart failure over a wide range of ejection fractions, regardless of whether the patients have type 2 diabetes. In addition to having glucosuric and natriuretic properties, these agents also reduce the risk of end-stage kidney disease in patients with type 2 diabetes and chronic kidney disease (NEJM)
Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
In this cohort study of older adults, starting a SGLT2 inhibitor versus DPP-4 inhibitor was not associated with a higher risk of skeletal fracture, regardless of eGFR (Clinical Journal of the American Society of Nephrology)
Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: a prospective cohort study
Greater %CV was associated with increased risk for all-cause mortality even among patients with seemingly well-controlled glucose status (Diabetes Research and Clinical Practice)
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
The primary objective of this article is to examine the clinical benefit, safety, and tolerability of the four SGLT2 inhibitors approved by the US FDA. SGLT2 inhibitors increase urinary glucose excretion via inhibiting SGLT2 to decrease renal reabsorption of filtered glucose and reduce the renal threshold for glucose (Cardiovascular Diabetology)
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin
As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin (Annals of Internal Medicine)
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients with DM treated with individual SGLT2 inhibitors using large-scale real-world data (Cardiovascular Diabetology)
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Type 2 diabetic AMI patients receiving SGLT2-I exhibited significantly reduced inflammatory response and smaller infarct size compared to those receiving other OAD agents independently of glucose-metabolic control (Cardiovascular Diabetology)
Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study
Use of SGLT2 inhibitors, as compared with GLP-1 receptor agonists, was not associated with a statistically significant increase in risk of bladder cancer (Diabetes Care)
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Global use of glucose-lowering medications with established cardiovascular benefits has increased over time but remains suboptimal, particularly in sub-groups most likely to benefit. Substantial country-level variability exists independent of patient factors, suggesting structural barriers may limit more widespread use of these medications (BMC Endocrine Disorders)
Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials
SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk and/or with CKD, without increasing the risk of hypokalemia
Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes
In T2D, a patient’s cardiovascular phenotype can help predict the pattern of future cardiovascular events (Clinical Research in Cardiology)
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes (Diabetes Therapy)
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Dapagliflozin contributes to the control of CV risk factors and reduces the risk of microvascular complications (nephropathy and retinopathy) and other non-classical complications of T2DM. The underuse of SGLT2i in general and dapagliflozin in particular, even in patients whose profiles suggest that they could greatly benefit from SGLT2i treatment, indicates that greater effort is needed to translate scientific evidence into actual clinical practice to improve patients’ quality of life (Diabetes Therapy )
Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function
Early intervention with SGLT2i may have renoprotective effects in T2D patients with rapid decline and preserved renal function (Journal of Diabetes Investigation)
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care (Diabetes Therapy)
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience
Our real-world data on SGLT2i showed promising results in reductions in HbA1c, weight, and insulin requirements in type 1 diabetes. Benefits were more pronounced in individuals with higher baseline HbA1c and BMI. DKA remained a major concern, despite educational measures (Diabetes Care)
Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis
SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Journal of Diabetes Research)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 13
- Next Page »
Glycosmedia is also available as an App: